email   Email Us: info@lupinepublishers.com phone   Call Us: +1 (914) 407-6109   57 West 57th Street, 3rd floor, New York - NY 10019, USA

ISSN: 2638-5945

Open Access Journal of Oncology and Medicine

Research Article(ISSN: 2638-5945)

Metastatic Hormone and Her-2 Positive Breast Cancer: A Community Approach

Volume 2 - Issue 1

Ida Micaily MD1*, Lakshmi Kolandra DO1, Shahrzad Abdollahi MD1 and Anthony Scarpaci MD2

  • Author Information Open or Close
    • 1Department of Internal Medicine, Abington Jefferson Health, Pennsylvania
    • 2Abington Cancer Care at the Rosenfeld Cancer Center, Abington Jefferson Health, Pennsylvania

    *Corresponding author: Ida Micaily, MD, Department of Internal Medicine, Abington Jefferson Health, Pennsylvania

Received: June 09, 2018;   Published: June 13, 2018

DOI: 10.32474/OAJOM.2018.02.000127

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Metastatic hormone-receptor and HER-2 positive (triple-positive) breast cancer provides a treatment dilemma for clinicians. The current guidelines offer a variety of options in the first and second line for metastatic breast cancer. A tailored treatment approach is needed for the triple-positive metastatic breast cancer population.

Objective: To trend the therapeutic treatment selections for patients with metastatic, triple-positive breast cancer at a single, community practice.

Methods: The Abington Jefferson Health Tumor Registry and electronic medical records systems were used to retrospectively identify patients with hormone and HER-2 positive metastatic disease who were treated at Abington Jefferson Health between 2010-2016.

Results: It was found that there was variability across our population in the choice of what therapy was chosen for first, second and fourth line of treatment. The majority of patients (12 out of 15) received combination therapy with trastuzumab. In the second line, 7 out 8 patients received trastuzumab as part of their treatment regimen. In the third line, all 3 patients received trastuzumab emtansine as part of their therapy regimen. For patients who were able to survive until the fourth line and beyond, several other treatments were used.

Limitations: A small sample size is the major limitation in this study.

Conclusion: Although HR+/ Her2+ (triple positive) cancer cell type represents a subset of patients with metastatic breast cancer, there is a general lack of consensus on how to best treat this patient population. More research needs to be conducted in order for community Oncologic practitioners to be able to better coordinate care for patients with triple positive, metastatic breast cancer.

Abstract| Introduction| Methods| Results| Conclusion| References|

Close

Online Submission System

Drag and drop files here

or

Browse Files
( For multiple files submission, zip them in a single file to submit. For file zipping software Download )